ClinVar Miner

Submissions for variant NM_001378609.3(OTOGL):c.2945A>C (p.Asp982Ala)

gnomAD frequency: 0.00006  dbSNP: rs774797627
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000612674 SCV000712495 uncertain significance not specified 2016-12-04 criteria provided, single submitter clinical testing Variant classified as Uncertain Significance - Favor Benign. The p.Asp973Ala var iant in OTOGL has not been previously reported in individuals with hearing loss, but has been identified in 2/54860 European chromosomes by the Genome Aggregati on Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs774797627). Aspar tate (Asp) at position 973 is not conserved in mammals or evolutionarily distant species and 2 mammals (Tasmanian devil and wallaby) carry an Alanine (Ala) at t his position, raising the possibility that this change may be tolerated. Additio nal computational prediction tools suggest that the p.Asp973Ala variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, while the clinical significance of the p.Asp973Ala v ariant is uncertain, these data suggest that it is more likely to be benign.
Fulgent Genetics, Fulgent Genetics RCV002491234 SCV002780559 uncertain significance Autosomal recessive nonsyndromic hearing loss 84B 2022-01-18 criteria provided, single submitter clinical testing
Ambry Genetics RCV004659123 SCV005155201 uncertain significance Inborn genetic diseases 2024-03-28 criteria provided, single submitter clinical testing The c.2918A>C (p.D973A) alteration is located in exon 26 (coding exon 26) of the OTOGL gene. This alteration results from a A to C substitution at nucleotide position 2918, causing the aspartic acid (D) at amino acid position 973 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.